FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 8081人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839908, encodeId=6da81839908a4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Verquvo治疗心力衰竭, objectType=article, longId=206205, objectId=26de20620550, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26de20620550, replyNumber=0, likeNumber=71, createdTime=2021-03-04, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26de20620550, moduleTitle=FDA批准Verquvo治疗心力衰竭, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26de20620550)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839929, encodeId=2930183992991, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Moderna新冠疫苗对青少年保护力达100％，有望在6月初获FDA批准, objectType=article, longId=211829, objectId=30232118293b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30232118293b, replyNumber=0, likeNumber=0, createdTime=2022-05-03, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30232118293b, moduleTitle=Moderna新冠疫苗对青少年保护力达100％，有望在6月初获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30232118293b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839928, encodeId=a89518399283c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准辉瑞/BioNTech新冠疫苗用于12-15岁青少年, objectType=article, longId=211125, objectId=10da2111256e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10da2111256e, replyNumber=0, likeNumber=62, createdTime=2021-10-23, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10da2111256e, moduleTitle=美国FDA批准辉瑞/BioNTech新冠疫苗用于12-15岁青少年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10da2111256e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839883, encodeId=7b54183988384, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=2020年1-10月FDA批准的41款新药，信息大汇总, objectType=article, longId=202719, objectId=0885202e19d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0885202e19d8, replyNumber=0, likeNumber=84, createdTime=2020-11-19, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0885202e19d8, moduleTitle=2020年1-10月FDA批准的41款新药，信息大汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0885202e19d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839918, encodeId=77e8183991830, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准PEPAXTO（美法仑氟苯甲酰胺）用于治疗复发难治多发性骨髓瘤, objectType=article, longId=207782, objectId=e4ee20e782e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4ee20e782e9, replyNumber=0, likeNumber=72, createdTime=2021-04-03, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4ee20e782e9, moduleTitle=FDA批准PEPAXTO（美法仑氟苯甲酰胺）用于治疗复发难治多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4ee20e782e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839911, encodeId=153d1839911ae, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=PFS、ORR翻倍，死亡风险降低40%！FDA批准卡博替尼联合Opdivo一线治疗肾癌, objectType=article, longId=206244, objectId=febb2062446f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=febb2062446f, replyNumber=0, likeNumber=104, createdTime=2021-06-26, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=febb2062446f, moduleTitle=PFS、ORR翻倍，死亡风险降低40%！FDA批准卡博替尼联合Opdivo一线治疗肾癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=febb2062446f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839917, encodeId=86b0183991e9a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Sarepta公司第3款反义寡核苷酸疗法获FDA批准上市, objectType=article, longId=207749, objectId=28a020e74967, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28a020e74967, replyNumber=0, likeNumber=72, createdTime=2022-02-13, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28a020e74967, moduleTitle=Sarepta公司第3款反义寡核苷酸疗法获FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28a020e74967)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839902, encodeId=81d11839902fe, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=【深度盘点】2020年FDA批准53款新药上市，肿瘤药占1/3, objectType=article, longId=204937, objectId=1aee20493e5e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1aee20493e5e, replyNumber=0, likeNumber=90, createdTime=2021-04-08, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1aee20493e5e, moduleTitle=【深度盘点】2020年FDA批准53款新药上市，肿瘤药占1/3, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1aee20493e5e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839935, encodeId=12741839935b1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准FreeStyle Libre 2 App用于糖尿病管理, objectType=article, longId=215880, objectId=02ea215880d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02ea215880d5, replyNumber=0, likeNumber=87, createdTime=2022-04-02, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02ea215880d5, moduleTitle=FDA批准FreeStyle Libre 2 App用于糖尿病管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02ea215880d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839930, encodeId=0da118399308f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准18年来**阿尔茨海默病新药aducanumab引争议, objectType=article, longId=212467, objectId=03d421246ed7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03d421246ed7, replyNumber=0, likeNumber=85, createdTime=2021-09-30, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03d421246ed7, moduleTitle=FDA批准18年来**阿尔茨海默病新药aducanumab引争议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03d421246ed7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839874, encodeId=bd8918398e470, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=多发性硬化症药物或添新成员：FDA批准ANK-700治疗多发性硬化症的IND, objectType=article, longId=201325, objectId=718d20132547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=718d20132547, replyNumber=0, likeNumber=94, createdTime=2020-10-11, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=718d20132547, moduleTitle=多发性硬化症药物或添新成员：FDA批准ANK-700治疗多发性硬化症的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=718d20132547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839923, encodeId=60b01839923b6, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=BMS的CAR-T细胞疗法治疗多发性骨髓瘤，已获得FDA批准, objectType=article, longId=209107, objectId=d5a420910e55, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5a420910e55, replyNumber=0, likeNumber=67, createdTime=2021-06-07, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5a420910e55, moduleTitle=BMS的CAR-T细胞疗法治疗多发性骨髓瘤，已获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5a420910e55)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839895, encodeId=80e71839895d6, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=创新靶向药RET抑制剂Pralsetinib扩展适应症获美国FDA批准，用于治疗甲状腺癌, objectType=article, longId=204067, objectId=48f320406e75, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48f320406e75, replyNumber=0, likeNumber=79, createdTime=2021-11-08, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48f320406e75, moduleTitle=创新靶向药RET抑制剂Pralsetinib扩展适应症获美国FDA批准，用于治疗甲状腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48f320406e75)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839934, encodeId=80bc1839934f0, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准数字疗法产品作为老年性痴呆突破性疗法地位, objectType=article, longId=215742, objectId=8367215e42be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8367215e42be, replyNumber=0, likeNumber=74, createdTime=2022-06-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8367215e42be, moduleTitle=FDA批准数字疗法产品作为老年性痴呆突破性疗法地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8367215e42be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839879, encodeId=cf5a18398e9af, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=再生元的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物, objectType=article, longId=202131, objectId=d48b202131f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d48b202131f6, replyNumber=0, likeNumber=32, createdTime=2021-09-16, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d48b202131f6, moduleTitle=再生元的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d48b202131f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839915, encodeId=7f3e1839915ca, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Cosela（trilaciclib）用于减少化学疗法引起的骨髓抑制, objectType=article, longId=207132, objectId=3ff420e132a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ff420e132a7, replyNumber=0, likeNumber=64, createdTime=2021-10-18, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ff420e132a7, moduleTitle=FDA批准Cosela（trilaciclib）用于减少化学疗法引起的骨髓抑制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ff420e132a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839893, encodeId=c5891839893a8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准AMZ002治疗婴儿癫痫病的III期临床试验, objectType=article, longId=203849, objectId=7f4820384995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f4820384995, replyNumber=0, likeNumber=60, createdTime=2021-10-02, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f4820384995, moduleTitle=FDA批准AMZ002治疗婴儿癫痫病的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f4820384995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839926, encodeId=648218399268b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=CD38抑制剂Sarclisa/卡非佐米/地塞米松（Kd）治疗晚期多发性骨髓瘤，已获FDA批准, objectType=article, longId=209632, objectId=570b20963284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=570b20963284, replyNumber=0, likeNumber=64, createdTime=2021-12-01, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=570b20963284, moduleTitle=CD38抑制剂Sarclisa/卡非佐米/地塞米松（Kd）治疗晚期多发性骨髓瘤，已获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=570b20963284)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839870, encodeId=5f8818398e031, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Onureg（azacitidine）治疗急性髓细胞性白血病（AML）, objectType=article, longId=200392, objectId=7b192003927b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b192003927b, replyNumber=0, likeNumber=56, createdTime=2020-11-18, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b192003927b, moduleTitle=FDA批准Onureg（azacitidine）治疗急性髓细胞性白血病（AML）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b192003927b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839896, encodeId=9a571839896d0, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准RET抑制剂pralsetinib新适应症！治疗甲状腺髓样癌, objectType=article, longId=204111, objectId=394820411175, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=394820411175, replyNumber=0, likeNumber=81, createdTime=2020-12-04, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=394820411175, moduleTitle=FDA批准RET抑制剂pralsetinib新适应症！治疗甲状腺髓样癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=394820411175)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Verquvo治疗心力衰竭

2021-03-04

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Moderna新冠疫苗对青少年保护力达100％，有望在6月初获FDA批准

2022-05-03

bugit (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准辉瑞/BioNTech新冠疫苗用于12-15岁青少年

2021-10-23

bugit (审核中...)

前往app查看评论内容

#FDA批准#

2020年1-10月FDA批准的41款新药，信息大汇总

2020-11-19

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准PEPAXTO（美法仑氟苯甲酰胺）用于治疗复发难治多发性骨髓瘤

2021-04-03

bugit (审核中...)

前往app查看评论内容

#FDA批准#

PFS、ORR翻倍，死亡风险降低40%！FDA批准卡博替尼联合Opdivo一线治疗肾癌

2021-06-26

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Sarepta公司第3款反义寡核苷酸疗法获FDA批准上市

2022-02-13

bugit (审核中...)

前往app查看评论内容

#FDA批准#

【深度盘点】2020年FDA批准53款新药上市，肿瘤药占1/3

2021-04-08

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准FreeStyle Libre 2 App用于糖尿病管理

2022-04-02

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准18年来**阿尔茨海默病新药aducanumab引争议

2021-09-30

bugit (审核中...)

前往app查看评论内容

#FDA批准#

多发性硬化症药物或添新成员：FDA批准ANK-700治疗多发性硬化症的IND

2020-10-11

bugit (审核中...)

前往app查看评论内容

#FDA批准#

BMS的CAR-T细胞疗法治疗多发性骨髓瘤，已获得FDA批准

2021-06-07

bugit (审核中...)

前往app查看评论内容

#FDA批准#

创新靶向药RET抑制剂Pralsetinib扩展适应症获美国FDA批准，用于治疗甲状腺癌

2021-11-08

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准数字疗法产品作为老年性痴呆突破性疗法地位

2022-06-17

bugit (审核中...)

前往app查看评论内容

#FDA批准#

再生元的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物

2021-09-16

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Cosela（trilaciclib）用于减少化学疗法引起的骨髓抑制

2021-10-18

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准AMZ002治疗婴儿癫痫病的III期临床试验

2021-10-02

bugit (审核中...)

前往app查看评论内容

#FDA批准#

CD38抑制剂Sarclisa/卡非佐米/地塞米松（Kd）治疗晚期多发性骨髓瘤，已获FDA批准

2021-12-01

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Onureg（azacitidine）治疗急性髓细胞性白血病（AML）

2020-11-18

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准RET抑制剂pralsetinib新适应症！治疗甲状腺髓样癌

2020-12-04

科室
- - 订阅+
  - 更多科室
工具
服务